VENERITO, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 2.746
AS - Asia 1.838
EU - Europa 1.296
SA - Sud America 460
AF - Africa 97
OC - Oceania 3
Totale 6.440
Nazione #
US - Stati Uniti d'America 2.661
SG - Singapore 871
BR - Brasile 364
CN - Cina 286
IT - Italia 285
HK - Hong Kong 234
RU - Federazione Russa 220
SE - Svezia 157
DE - Germania 151
FR - Francia 137
VN - Vietnam 126
FI - Finlandia 107
GB - Regno Unito 80
IN - India 76
CA - Canada 46
BD - Bangladesh 39
AR - Argentina 38
ID - Indonesia 34
JP - Giappone 31
ZA - Sudafrica 28
CI - Costa d'Avorio 26
MX - Messico 25
NL - Olanda 25
IQ - Iraq 23
PK - Pakistan 21
TR - Turchia 19
BE - Belgio 17
PL - Polonia 16
AT - Austria 15
ES - Italia 15
UA - Ucraina 15
VE - Venezuela 14
CZ - Repubblica Ceca 13
LT - Lituania 13
CO - Colombia 12
EC - Ecuador 12
MA - Marocco 12
SA - Arabia Saudita 12
PH - Filippine 10
CL - Cile 8
UZ - Uzbekistan 8
DZ - Algeria 7
MY - Malesia 7
TN - Tunisia 6
IR - Iran 5
KZ - Kazakistan 5
NP - Nepal 5
BB - Barbados 4
BO - Bolivia 4
DK - Danimarca 4
KE - Kenya 4
SN - Senegal 4
AU - Australia 3
EG - Egitto 3
IE - Irlanda 3
IL - Israele 3
JM - Giamaica 3
LB - Libano 3
NI - Nicaragua 3
PY - Paraguay 3
SI - Slovenia 3
UY - Uruguay 3
AZ - Azerbaigian 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GH - Ghana 2
KG - Kirghizistan 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
FO - Isole Faroe 1
GF - Guiana Francese 1
GI - Gibilterra 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KR - Corea 1
KW - Kuwait 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NG - Nigeria 1
PA - Panama 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.436
Città #
Singapore 506
Ashburn 415
Hong Kong 231
San Jose 216
Chandler 199
Fairfield 183
Beijing 141
Nyköping 136
Dallas 105
Houston 82
Woodbridge 81
Helsinki 80
Cambridge 73
Lauterbourg 72
Los Angeles 72
New York 68
Seattle 67
Munich 55
Wilmington 52
Falkenstein 50
Ho Chi Minh City 47
Ann Arbor 43
Bari 43
Moscow 41
Council Bluffs 39
São Paulo 37
Lawrence 32
Santa Clara 32
Roxbury 30
Turku 27
Abidjan 26
Inglewood 25
Jakarta 24
Hanoi 23
Tokyo 23
Buffalo 21
Jacksonville 21
Des Moines 20
London 20
Johannesburg 19
Brooklyn 18
Montreal 18
Brussels 17
Chicago 16
Mexico City 16
Pune 16
Denver 14
Toronto 14
Milan 13
Belo Horizonte 12
Warsaw 12
Frankfurt am Main 11
Atlanta 10
Elk Grove Village 10
Manchester 10
Nuremberg 10
Paris 10
Brno 9
Dhaka 9
Poplar 9
San Diego 9
San Francisco 9
Chennai 8
Rio de Janeiro 8
Rome 8
Shanghai 8
Boston 7
Campinas 7
Goiânia 7
Guarulhos 7
Lahore 7
Mumbai 7
Nanjing 7
Orem 7
Stockholm 7
Ankara 6
Baghdad 6
Brasília 6
Caracas 6
Charlotte 6
Columbus 6
Florence 6
Phoenix 6
Redwood City 6
Salt Lake City 6
Brindisi 5
Casablanca 5
Curitiba 5
Naples 5
Ottawa 5
Roubaix 5
Shenyang 5
Taranto 5
The Dalles 5
Tunis 5
Vienna 5
Amsterdam 4
Bridgetown 4
Dakar 4
Dearborn 4
Totale 3.975
Nome #
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 187
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 179
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 174
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 164
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 156
A machine learning tool to predict the response to neoadjuvant chemotherapy in patients with locally advanced cervical cancer 142
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis 133
Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification 128
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 126
Formalin-fixed and paraffin-embedded samples for next generation sequencing: Problems and solutions 124
A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study 123
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 122
The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients 119
Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis 118
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 114
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 112
Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study 107
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab 107
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 106
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey 105
Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23 104
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors 99
Anakinra effectiveness in refractory polyserositis: An Italian multicenter study 98
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry 97
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis 90
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis 90
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus 88
Complete Hydatidiform Mole Mimicking Sacroiliitis 88
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 87
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis 86
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 83
Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis 82
Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy 81
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease 81
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 80
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 80
Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behḉet’s disease using explainable artificial intelligence 79
Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection 79
Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy 78
Machine learning applied to MRI evaluation for the detection of lymph node metastasis in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy 74
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents 74
Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI) 74
Radiomics analysis in ovarian cancer: A narrative review 74
null 71
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors 69
AI am a rheumatologist: A practical primer to large language models for rheumatologists 67
Safety of systemic treatments for Behçet’s syndrome 67
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis 66
Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast 65
Cytokine signatures in mucocutaneous and Ocular Behçet's disease 64
Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult with Seronegative Rheumatoid Arthritis 64
The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review 64
Letters to the editors 63
Erratum: Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus (Rheumatology (2020) 59 (1188) DOI: 10.1093/rheumatology/kez442) 61
Efficacité de l'anakinra dans la polysérite réfractaire : étude multicentrique italienne 59
Management of takayasu arteritis diagnosed during pregnancy: A case report 56
Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF) 55
Prompt engineering: The next big skill in rheumatology research 55
Exploring the oral microbiome in rheumatic diseases, state of art and future prospective in personalized medicine with an ai approach 55
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases 54
COVID-19 Vaccine Knowledge, Attitude, Acceptance and Hesitancy among Pregnancy and Breastfeeding: Systematic Review of Hospital-Based Studies 53
The impact of multimorbidity on QoL in inflammatory myopathies: COVAD cluster analysis 53
Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study 53
COVAD survey 2 long-term outcomes: unmet need and protocol 52
Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre 51
Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease 51
Reply to Praprotnik and Tomsic and erratum corrige 50
Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium” 49
Radiomics to predict the mortality of patients with rheumatoid arthritis-associated interstitial lung disease: A proof-of-concept study 49
Paradoxical Pustular Psoriasis in a Patient with Psoriatic Arthritis on Secukinumab Treatment 47
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study 46
COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence 44
Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study 44
Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study 43
Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk 40
Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study 38
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 37
Predictors of long-term clinical remission in rheumatoid arthritis 36
Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort 33
Uncovering the Underworld of Axial Spondyloarthritis 33
Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study 25
Integrating large language models in medicine: a study of Claude 2’s performance in MDAAT scoring for idiopathic inflammatory myopathies 22
null 22
Update on the Medical Management of Gastrointestinal Behçet's Disease 21
Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis 21
Harnessing the potential of digital rheumatology 19
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 18
Beyond the horizon: Innovations and future directions in axial-spondyloarthritis 18
Response to: ‘Response to: “Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients” by Fornaro et al‘ by Agca et al 16
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations 12
Editorial: New insights into spondyloarthritis: from bench to bedside 4
Totale 6.747
Categoria #
all - tutte 31.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.997


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 34 29 19
2021/2022264 9 5 5 8 10 22 23 10 22 35 46 69
2022/2023589 48 86 32 32 41 111 13 83 92 4 33 14
2023/2024320 22 55 18 28 29 67 5 27 3 13 5 48
2024/20251.622 45 29 60 29 34 141 192 260 68 119 217 428
2025/20263.151 498 149 277 397 437 214 394 122 378 285 0 0
Totale 6.747